Stay updated on Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.

Latest updates to the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page
- Check5 days agoChange DetectedThe site footer now identifies the ClinicalTrials.gov page as revision v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check12 days agoChange DetectedThe ClinicalTrials.gov page now displays the melanoma trial record, including its study details, eligibility criteria, outcomes, and documents, in place of a 403 error screen.SummaryDifference55%

- Check19 days agoChange DetectedThe site revision identifier in the footer changed from v3.7.2 to v3.8.0; the study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check33 days agoChange DetectedAn NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence,” and the site revision label changes from v3.7.1 to v3.7.2. The study page itself continues to display a 403 error.SummaryDifference1%

- Check47 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changed from v3.7.0 to v3.7.1; the study page continues to display a 403 error.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now renders a 403 Forbidden error instead of the study record content. The detailed study information and navigation have been replaced by an error page.SummaryDifference20%

Stay in the know with updates to Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.